AANEM News Express

AANEM News Express

Science News: Placebo Effect in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study and a Systematic Review

1/20/2021
 
NSEB.jpgSubmitted by: Pritikanta Paul, MD
Edited by: Elliot Bodofsky, MD

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
Lewis et al. J Peripher Nerv Syst. 2020 Sep;25 (3) :230-237

Summary: Placebos (pharmacologically inert preparations) are used in treatment trials to assess the true effect of trial medication. Placebo responses have been noted in CIDP trials including the most recent PATH trial investigating subcutaneous IVIG as maintenance therapy. A post-hoc analysis of the placebo group in the PATH study was recently published. Although all randomised subjects were proven to deteriorate off IVIG, 37% of the placebo group remained clinically stable on placebo over 6 months. Placebo effect correlated with older age, more severe disease, and yet more stable disease. The authors also performed meta-analyses of placebo controlled CIDP studies and noted the placebo effect was higher when primary outcome is measuring relapse versus measuring improvement.

Comments: Age, disease severity, and stability can affect placebo response. Also future CIDP trials should consider how primary endpoint in study design can influence placebo outcome and hence statistical analysis.

 


View Related News Stories:

  EducationScience News NSEB


Recent AANEM News

Science News: Peripheral Nerve Compression Syndromes in Children

Science News: Serum Neurofilament Light Chain Predicts Long-Term Prognosis in Guillain-Barré Syndrome Patients

Latest Anthology of Articles from the News Science Editorial Board Now Available

Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series

President Biden’s Initial Health Care Priorities





Advertisement

ABEM

Advertisement

Donate

Advertisement

SAE